HBIO Harvard Bioscience Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
21:32
Mar 29
Mar 29
BroadOak activist has a board seat and the company trades at 6.4x forward P/E. The article notes 'cheaply valued' and a 'clear value realization opportunity' with an engaged activist pushing for opera
BroadOak activist has a board seat and the company trades at 6.4x forward P/E. The article notes 'cheaply valued' and a 'clear value realization opportunity' with an engaged activist pushing for operational improvements or strategic alternatives.
Risk: Micro-cap liquidity and potential resistance from management.
14:39
Jan 12
Jan 12
Refinanced debt, new CEO, earnings catalyst
The author argues HBIO dropped below $1 only due to bad management, and that a new CEO plus a completed debt refinancing put the company in a position where it is in its own interest to keep the ticker listed. He expects upcoming earnings to confirm strong financials, betting the stock hits $1+. The stated risk is that investors are waiting to confirm the last quarter's financials before buying.
HIGH
About HBIO Investor Commentary
Across the available history and selected sources, Buzzberg tracks HBIO (Harvard Bioscience Inc.) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Clark Square Capital, u/Legal-Industry-731.